<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201643</url>
  </required_header>
  <id_info>
    <org_study_id>OBX0001</org_study_id>
    <secondary_id>OBX0001</secondary_id>
    <nct_id>NCT00201643</nct_id>
  </id_info>
  <brief_title>A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome</brief_title>
  <acronym>ACS</acronym>
  <official_title>A Randomized Double-Blinded Study Comparing the Impact of One Versus Two Courses of Antenatal Steroids on Neonatal Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Obstetrix Medical Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mednax Center for Research, Education, Quality and Safety</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that administration of two courses of antenatal corticosteroids, compared
      to one course, will show a 40% reduction in the incidence of composite neonatal morbidity in
      patients delivering prior to 34 weeks' gestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blinded placebo-controlled trial. The objective of this study is
      to evaluate the impact of one versus two courses of antenatal steroids on the incidence of
      major neonatal morbidity including respiratory distress syndrome in patients delivering prior
      to 34 weeks' gestation in a randomized prospective fashion.

      Preterm delivery occurs in approximately 10% of all deliveries in the United States. Preterm
      birth is the cause of 75% of neonatal mortality not mentioning the significantly increased
      morbidity from respiratory distress syndrome, intraventricular hemorrhage, necrotizing
      enterocolitis, and sepsis. Numerous studies have evaluated the safety and efficacy of
      antenatal corticosteroid (ACS) administration in threatened preterm labor.

      National Institutes of Health (NIH) first consensus conference in 1994 evaluated the research
      in this field. Conclusions included the clear evidence that antenatal corticosteroids
      decrease the incidence of RDS in infants born at 29-34 weeks gestation, with a decrease in
      RDS severity for infants born at 24-28 weeks gestation and a decrease in the incidence of
      intraventricular hemorrhage in infants born at 24-28 weeks gestation without harm to mother
      or fetus. Their recommendation was to give a single course of corticosteroids to all pregnant
      women between 24 and 34 weeks gestation who are at risk of preterm delivery within 7 days.

      Since the studies on the duration of the effects of antenatal corticosteroids in the fetus
      are not conclusive, many obstetricians repeat corticosteroids weekly or bi-weekly to patients
      continuing to be at risk for preterm delivery. Lacking scientific evidence, many
      investigators have performed retrospective analyses regarding the effects of single-course
      versus multiple-course antenatal corticosteroids.

      The NIH consensus panel reconvened in 2000 and concluded that studies regarding repeated
      courses of corticosteroids are suggestive of possible benefits, especially in reduction of
      RDS, however, design flaws limit their validity.

      The more recent publication from Caughey and Parer examined the literature for evidence
      regarding a dose response of the benefits and detriments of antenatal corticosteroids. Based
      on their complex mathematical analysis they recommend all fetus' between 24 and 34 weeks'
      gestation at risk for preterm delivery should be given a first course of ANC. If the risk of
      preterm delivery persists the next course should be given 2 weeks later, for a maximum of two
      courses. Consistent with all previous articles, the call for a well designed randomized,
      controlled trial is made.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Neonatal Morbidity &lt; 34 Weeks Gestation at Time of Birth.</measure>
    <time_frame>From birth to 28 days of life</time_frame>
    <description>This outcome measured the total number of neonates with Composite Neonatal morbidity who delivered at &lt; 34 weeks gestation. Composite Morbidity consisted of respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis, or perinatal death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at (@) Delivery</measure>
    <time_frame>gestational age at delivery in weeks of gestation</time_frame>
    <description>Reported the average/mean Neonatal gestational age (GA) (reported in weeks of pregnancy) at the time of birth for both groups (ACS vs. Placebo).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Birth Weight Reported in Grams</measure>
    <time_frame>At time of Birth</time_frame>
    <description>Measured mean Birth weights of Neonates in each arm as reported in grams on the birth record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interuterine Growth Restriction (IUGR) or Small for Gestational Age(SGA)in Babies Delivering at &lt; 34 Weeks Gestation.</measure>
    <time_frame>Measured at birth.</time_frame>
    <description>Noted as the total number of Neonates delivering at &lt; 34 weeks gestation for which their weights fell within the 10th percentile at time of birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Head Circumference Taken at Time of Birth.</measure>
    <time_frame>Birth</time_frame>
    <description>Reported as the average of all neonatal head circumferences (HC) taken at time of birth in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Babies Who Required Ventilatory Support Within the First 28 Days of Life.</measure>
    <time_frame>birth to 28 days of life</time_frame>
    <description>The number of babies who required ventilatory support within the first 28 days of life. Equal to or great than 12 hours was considered one day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates Who Required Surfactant Therapy After Birth.</measure>
    <time_frame>Birth to 28 days of life</time_frame>
    <description>The Number of neonates who required surfactant therapy within the first 28 days after birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Pneumothorax</measure>
    <time_frame>birth to 28 days of life</time_frame>
    <description>Total number of neonates with pneumothorax diagnosed postpartum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Infectious Morbidity.</measure>
    <time_frame>Up to 28 days after giving birth</time_frame>
    <description>Total number of Mothers having Maternal infectious morbidity (e.g. endometritis &amp; maternal sepsis) noted from birth through 28 days after birth</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">437</enrollment>
  <condition>Preterm Delivery</condition>
  <arm_group>
    <arm_group_label>1 Test group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive 2nd Course = Study drug (betamethasone or dexamethasone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group = received placebo course</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone or Dexamethasone (2nd course of ACS)</intervention_name>
    <description>Course of Betamethasone or Dexamethasone</description>
    <arm_group_label>1 Test group</arm_group_label>
    <other_name>Beta</other_name>
    <other_name>Dex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Course of Placebo (NS)</description>
    <arm_group_label>2 - Control</arm_group_label>
    <other_name>Placebo, Normal Saline.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25 to 32 6/7 weeks gestation

          -  Singleton or twin gestation

          -  Received 1st course of betamethasone prior to 30 weeks' gestation

          -  Began 1st course of betamethasone at least 14 days prior to randomization

          -  Risk of delivery in next 7 days due to either maternal or fetal complication (e.g.
             preterm labor, severe preeclampsia, IUGR, etc.)

          -  Intact membranes

        Exclusion Criteria:

          -  Known major fetal anomalies (eg: anencephaly, renal agenesis etc…)

          -  High order multiple gestation (triplets or higher)

          -  Cervical dilation &gt; 5 cm

          -  Clinical chorioamnionitis prior to initiation of second course (two or more of the
             following; antepartum temperature &gt; 38ºC (100.4ºF), uterine tenderness, foul smelling
             vaginal discharge or amniotic fluid, maternal tachycardia (&gt;100beats/min), fetal
             tachycardia (&gt;160 beats/min), or white blood cell count &gt;20x109/L.define)

          -  Ruptured membranes prior to initiation of second course of betamethasone

          -  Already receiving corticosteroids for other conditions (e.g. Lupus, asthma)

          -  Maternal condition contraindicating the use of steroids (e.g. HIV, active
             Tuberculosis)

          -  Participation in conflicting study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Maurel, RN, MSN, CNS</last_name>
    <role>Study Director</role>
    <affiliation>Obstetrix Medical Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Desert Good Samaritan Hospital</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Good Sammaritan Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tucson Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saddleback Memorial Medical Center</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801-1428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sourthern California-Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian/St Luke's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyridge Medical Center</name>
      <address>
        <city>Lonetree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital, Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John's Regional Health Center</name>
      <address>
        <city>Springfield,</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Med. Ctr. of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlanger Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Hospital</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pediatrix.com/body_university.cfm?id=96&amp;oTopID=92</url>
    <description>Protocols' home page on the sponsor's Web site. Click on Protocols and then click the ACS Protocol for more information about this study.</description>
  </link>
  <reference>
    <citation>Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement. 1994 Feb 28-Mar 2;12(2):1-24. Review.</citation>
    <PMID>7728157</PMID>
  </reference>
  <reference>
    <citation>Vermillion ST, Soper DE, Newman RB. Is betamethasone effective longer than 7 days after treatment? Obstet Gynecol. 2001 Apr;97(4):491-3.</citation>
    <PMID>11275015</PMID>
  </reference>
  <reference>
    <citation>Antenatal corticosteroids revisited: repeat courses. NIH Consens Statement. 2000 Aug 17-18;17(2):1-18.</citation>
    <PMID>11725806</PMID>
  </reference>
  <reference>
    <citation>Guinn DA, Atkinson MW, Sullivan L, Lee M, MacGregor S, Parilla BV, Davies J, Hanlon-Lundberg K, Simpson L, Stone J, Wing D, Ogasawara K, Muraskas J. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial. JAMA. 2001 Oct 3;286(13):1581-7.</citation>
    <PMID>11585480</PMID>
  </reference>
  <reference>
    <citation>Caughey AB, Parer JT. Recommendations for repeat courses of antenatal corticosteroids: a decision analysis. Am J Obstet Gynecol. 2002 Jun;186(6):1221-6; discussion 1226-9.</citation>
    <PMID>12066102</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>September 7, 2010</results_first_submitted>
  <results_first_submitted_qc>February 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2011</results_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preterm Labor</keyword>
  <keyword>Preterm delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pregnant women were recruited at 18 private (15) and university (3) medical centers from May 2003 through February 2008.</recruitment_details>
      <pre_assignment_details>no washout, run-in or transition events occurred between enrollment and group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
          <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Normal Saline)</title>
          <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
          <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Normal Saline)</title>
          <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="223"/>
            <count group_id="B2" value="214"/>
            <count group_id="B3" value="437"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="6"/>
                    <measurement group_id="B2" value="29" spread="6"/>
                    <measurement group_id="B3" value="29" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Neonatal Morbidity &lt; 34 Weeks Gestation at Time of Birth.</title>
        <description>This outcome measured the total number of neonates with Composite Neonatal morbidity who delivered at &lt; 34 weeks gestation. Composite Morbidity consisted of respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis, or perinatal death</description>
        <time_frame>From birth to 28 days of life</time_frame>
        <population>This was an intent to treat protocol. In patients delivering before 34 weeks we estimated that the sample size of at least 217 subjects in each arm would be needed to have 80% power to detect a 40% reduction in neonatal morbidity (to 16.8%).</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Neonatal Morbidity &lt; 34 Weeks Gestation at Time of Birth.</title>
          <description>This outcome measured the total number of neonates with Composite Neonatal morbidity who delivered at &lt; 34 weeks gestation. Composite Morbidity consisted of respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis, or perinatal death</description>
          <population>This was an intent to treat protocol. In patients delivering before 34 weeks we estimated that the sample size of at least 217 subjects in each arm would be needed to have 80% power to detect a 40% reduction in neonatal morbidity (to 16.8%).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Our Hypothesis was that administration of a rescue ACS would show a 40% reduction in incidence of composite neonatal morbity in patients delivering &lt; 34 weeks. Sample size estimates based on composite morbidity of 28%. Each arm required 217 subjects to have 80% power to detect a 40% reduction to 16.8%(2-tailed,alpha =0.05)using comparison for proportions/groups(Fisher exact test) OR,95% CI &amp; P values were determined using a repeated measure model where each twin is considered a repeat measure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Analysis were also conducted in all randomized women with a known outcome &amp; in randomized treatment group(modified intent to treat). Analysis of the primary outcome used a repeated measures approach where each baby was considered a repeated measure</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1162</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at (@) Delivery</title>
        <description>Reported the average/mean Neonatal gestational age (GA) (reported in weeks of pregnancy) at the time of birth for both groups (ACS vs. Placebo).</description>
        <time_frame>gestational age at delivery in weeks of gestation</time_frame>
        <population>Modified intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age at (@) Delivery</title>
          <description>Reported the average/mean Neonatal gestational age (GA) (reported in weeks of pregnancy) at the time of birth for both groups (ACS vs. Placebo).</description>
          <population>Modified intent to treat</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="3.1"/>
                    <measurement group_id="O2" value="33.0" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Birth Weight Reported in Grams</title>
        <description>Measured mean Birth weights of Neonates in each arm as reported in grams on the birth record.</description>
        <time_frame>At time of Birth</time_frame>
        <population>Intent to treat protocol</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Birth Weight Reported in Grams</title>
          <description>Measured mean Birth weights of Neonates in each arm as reported in grams on the birth record.</description>
          <population>Intent to treat protocol</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1905" spread="738"/>
                    <measurement group_id="O2" value="1920" spread="667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interuterine Growth Restriction (IUGR) or Small for Gestational Age(SGA)in Babies Delivering at &lt; 34 Weeks Gestation.</title>
        <description>Noted as the total number of Neonates delivering at &lt; 34 weeks gestation for which their weights fell within the 10th percentile at time of birth.</description>
        <time_frame>Measured at birth.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Interuterine Growth Restriction (IUGR) or Small for Gestational Age(SGA)in Babies Delivering at &lt; 34 Weeks Gestation.</title>
          <description>Noted as the total number of Neonates delivering at &lt; 34 weeks gestation for which their weights fell within the 10th percentile at time of birth.</description>
          <population>Intent to Treat</population>
          <units>paticipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Head Circumference Taken at Time of Birth.</title>
        <description>Reported as the average of all neonatal head circumferences (HC) taken at time of birth in each group.</description>
        <time_frame>Birth</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Head Circumference Taken at Time of Birth.</title>
          <description>Reported as the average of all neonatal head circumferences (HC) taken at time of birth in each group.</description>
          <population>Intent to treat</population>
          <units>centemeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="3.0"/>
                    <measurement group_id="O2" value="30.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Babies Who Required Ventilatory Support Within the First 28 Days of Life.</title>
        <description>The number of babies who required ventilatory support within the first 28 days of life. Equal to or great than 12 hours was considered one day.</description>
        <time_frame>birth to 28 days of life</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Babies Who Required Ventilatory Support Within the First 28 Days of Life.</title>
          <description>The number of babies who required ventilatory support within the first 28 days of life. Equal to or great than 12 hours was considered one day.</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates Who Required Surfactant Therapy After Birth.</title>
        <description>The Number of neonates who required surfactant therapy within the first 28 days after birth.</description>
        <time_frame>Birth to 28 days of life</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates Who Required Surfactant Therapy After Birth.</title>
          <description>The Number of neonates who required surfactant therapy within the first 28 days after birth.</description>
          <population>ITT</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Pneumothorax</title>
        <description>Total number of neonates with pneumothorax diagnosed postpartum.</description>
        <time_frame>birth to 28 days of life</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Pneumothorax</title>
          <description>Total number of neonates with pneumothorax diagnosed postpartum.</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Infectious Morbidity.</title>
        <description>Total number of Mothers having Maternal infectious morbidity (e.g. endometritis &amp; maternal sepsis) noted from birth through 28 days after birth</description>
        <time_frame>Up to 28 days after giving birth</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
            <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Infectious Morbidity.</title>
          <description>Total number of Mothers having Maternal infectious morbidity (e.g. endometritis &amp; maternal sepsis) noted from birth through 28 days after birth</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and (&amp;) 9 months</time_frame>
      <desc>Evaluation of AEs occurred from randomization until 28days post delivery/discharge.
The difference in reporting number(#)of participants at risk reflects the group for which the event relates to.e.g.: neonatal event N 289=test arm &amp; 288=placebo
maternal event N 223=test arm &amp; 214=placebo
maternal &amp; neonatal 512= test arm &amp; 502=placebo</desc>
      <group_list>
        <group group_id="E1">
          <title>&quot;Rescue&quot; Course of Betamethasone or Dexamethasone</title>
          <description>Receive 2nd &quot;Rescue&quot; Course = Study drug (betamethasone or dexamethasone. If Dexamethasone, administered 6 mg IM q 12 hours x 4 doses total. If Betamethasone was used, 2 doses of 12 mg of betamethasone was given intramuscularly (IM) 24 hours apart.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Normal Saline)</title>
          <description>Placebo consisted of quantity sufficient of Normal Saline with preservatives, Benzylalcohol and Benzylbenzoate.
The research subject received 2 doses of pharmacy prepared placebo (2ml normal saline)to conceal administration of dexamethasone or if to conceal betamethasone, 2 doses of Placebo (2ml normal saline) given IM 24 hours apart.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="512"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Cardiac Dysfunction</sub_title>
                <description>Arrhythmias, cardiomyopathy, hypoperfusion</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Defect</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>to include: Congenital heart defects, hypospadias, inguinal hernia, hydrocele, dysmorphology, Cleft Lip, VATERS.</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Small Bowel Rotation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Ruptured Appendix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubenemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegally</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post delivery/C/S hemorrage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Spinal Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>soft tissue rectal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Intraoperative Bladder Tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>PVL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Intraventicular Hemorrage (Grade III, IV)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Perinatal fetal demise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Abruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea/respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pulmonary Disease</sub_title>
                <description>Bronchiolitis, Pulmonary Interstitial Glycogenesis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>D &amp; C for retained products</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly A. Maurel, MSN, CNS</name_or_title>
      <organization>Obstetrix Medical Group, Inc.</organization>
      <phone>714-593-9171</phone>
      <email>kimberly_maurel@pediatrix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

